WAs the number of antimicrobial-resistant infections worldwide is growing exponentially, the need for feasible and effective alternatives to antibiotics has skyrocketed. Drug developers are combating antibiotic resistance by translating bacteriophages into robust clinical candidates and are navigating the regulatory challenges with GMP manufacturing.
The 7th Bacteriophage Therapy Summit will unite industry leaders, such as Armata Pharmaceuticals, Phiogen Pharma, and TechnoPhage as they share clinical data, dive into the investment opportunities for bacteriophage companies, and tackle the regulatory challenges in development.
Top 5 Reasons to Attend:
DISSECT
the guidance for live biotics from regulatory bodies to improve the path of bacteriophages to the clinic with TechnoPhage, Nexabiome, and Precisio Biotix Therapeutics
OVERCOME
the investment uncertainty for bacteriophage companies to obtain funding to proceed to the clinic and prove the therapy as an alternative to antibiotics
DISCOVER
the most recent updates from pivotal clinical trials with Armata Pharmaceuticals as they move beyond compassionate use of bacteriophages to fight AMR bacteria
DEBATE
the advantages of personalized and off-the-shelf bacteriophage cocktails in different disease indications to rapidly respond to infection with Kinzbio
DIVE INTO
the challenges of sustainable commercialization of bacteriophages post-approval, considering the reimbursement strategy, with Cytophage and PhagePro
